Researchers have revealed that the use of Lynparza® to treat BRCA-mutated ovarian cancer results in a significant improvement in progression-free survival.
Browsing: Disease Area > Gynecologic
A recent study has demonstrated a significant decrease in cases of HPV infections in England since the introduction of a bivalent vaccine in 2008.
A team of researchers have identified the cause of resistance to breakthrough breast and ovarian cancer drugs.
Discover details of the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
Discover the case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatments and demonstrated a striking response to pembrolizumab.
Blueberry extract has been shown to improve success rate of radiation therapy in patients with cervical cancer.
Researchers from the Case Western Reserve University (OH, USA) have demonstrated how a computer program can suggest novel cancer treatments.
A new study has demonstrated that women may only need three cervical screens in their lifetime if they have received the HPV vaccine.